Published in Gene Therapy Weekly, September 1st, 2011
"Their capsids can be modified in precise locations via genetic insertion or chemical conjugation, facilitating the multivalent display of targeting ligands. MS2 VU's also self-assemble in the presence of nucleic adds to specifically encapsidate siRNA and RNA-modified cargos. Here we report the use of MS2 VLPs to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.